RxDoctor Payments Data

Dov Markowitz, PA

Physician Assistant · Monroe, NYNPI 1295080653

Payments from drug & device makers

$861in general payments, 2019–2025

Across 15 payments — averaging $57.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$305
  • Regeneron Healthcare Solutions, Inc.$125
  • Novo Nordisk$113
  • Biogen$100
  • Johnson & Johnson$100
  • AbbVie$41
  • plus $77 from 3 others

What the payments were for

  • Food & beverage$861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$861 in reported general payments places this provider in the 70th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$94,544
Medicare patients
304
Services billed
1,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept12$85,152
OzempicSemaglutide83$80,613
RybelsusSemaglutide47$52,439
EliquisApixaban43$29,679
FarxigaDapagliflozin Propanediol34$18,646
XareltoRivaroxaban20$17,994
JardianceEmpagliflozin15$14,192
JanumetSitagliptin Phos/Metformin Hcl21$11,775
TrintellixVortioxetine Hydrobromide25$11,463
InvokametCanagliflozin/Metformin Hcl12$7,438
LinzessLinaclotide12$6,532
NexiumEsomeprazole Magnesium21$5,969
VascepaIcosapent Ethyl13$4,330
Ketoconazole35$2,986
Fluoxetine Hcl52$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$113$133,052130 claims
Johnson & JohnsonXarelto, Invokamet$100$25,43232 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$20$11,46325 claims
AbbVieLinzess$41$6,53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Monroe

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →